On Apr. 19, 2021, Resverlogix announced the publishing of an article titled: ﾓBromodomain and extraterminal protein inhibitor, apabetalone (RVX-208), reduced ACE2 expression and attenuates SARS-CoV-2 infection in vitroﾔ, in Biomedicines, a high-impact scientific journal.

The previously announced findings, made in collaboration with Dr. Dalia ElGamalﾒs research group at the University of Nebraska Medical Center (UNMC), Omaha, NE, completed the peer-review process.